Miller, A. M. and Liew, F. Y. (2011) The IL-33/ST2 pathway — A new therapeutic target in cardiovascular disease. Pharmacology and Therapeutics, 131(2), pp. 179-186. (doi: 10.1016/j.pharmthera.2011.02.005)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1016/j.pharmthera.2011.02.005
Abstract
Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological effects of IL-33 are limited by a soluble decoy form of ST2 (sST2). Recent studies indicate a protective role for IL-33 and ST2L in atherosclerosis, obesity and cardiac remodeling. The present review summarizes currently available data showing the role for IL-33 and its receptor ST2L within cardiovascular disease, and the potential use of sST2 as a predictive cardiovascular biomarker.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Liew, Prof Foo and Miller, Dr Ashley |
| Authors: | Miller, A. M., and Liew, F. Y. |
| Subjects: | R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
| College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
| Journal Name: | Pharmacology and Therapeutics |
| Journal Abbr.: | Pharmacol. Ther. |
| Publisher: | Elsevier |
| ISSN: | 0163-7258 |
| ISSN (Online): | 1879-016X |
| Published Online: | 26 February 2011 |
| Related URLs: |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information